Study Results from Yokosuka Kyosai Hospital Broaden Understanding of Bladder Cancer (Comparative Analysis of Risk Stratifications for Non-muscle-invasive Bladder Cancer According To the Classifications Provided By the National Comprehensive …): Oncology – Bladder Cancer

2026 JUN 01 (NewsRx) -- By a News Reporter-Staff News Editor at Japan Daily Report -- Current study results on Oncology - Bladder Cancer have been published. According to news originating from Yokosuka, Japan, by NewsRx correspondents, research stated, “We compared NCCN, EAU, and JUA risk stratifications for non-muscle-invasive bladder cancer in 591 patients. All systems correlated with recurrence and progression, but predictive performance differed by endpoint.”

Our news journalists obtained a quote from the research from Yokosuka Kyosai Hospital, “Higher risk categories consistently predicted intravesical and early recurrence, while associations with grade and stage progression varied among classifications. Risk stratification systems for non-muscle-invasive bladder cancer (NMIBC) differ among the National (EAU), and Japanese Urological Association (JUA) guidelines, and their comparative ability to predict clinical outcomes in real-world practice remains unclear. We retrospectively analyzed 591 patients who underwent transurethral resection of bladder tumor and classified them into risk categories according to the NCCN, EAU, and JUA guidelines, comparing recurrence and progression outcomes among classifications. During median follow-up of 64.1 months, intravesical recurrence (32.1%), T stage progression (4.5%), grade progression (2.5%), undergoing radical nephroureterectomy (2.7%), and radical cystectomy (5.3%) were observed, respectively. Grade progression from low-grade to high-grade disease was significantly associated with increasing EAU risk ( P = .026) but not with NCCN or JUA classifications. Among pTa tumors, progression to >= pT1 occurred more frequently in higher risk groups across all classifications (all, P< .05), whereas progression from pT1 to pT2 was not significantly stratified by any system. Early intravesical recurrence increased with higher risk in all classifications (all, P< .05), with the strongest discrimination observed for the NCCN system. In multivariable Cox proportional hazards analyses, the NCCN classification demonstrated the highest discriminative performance for predicting intravesical recurrence.”

According to the news editors, the research concluded: “The NCCN, EAU, and JUA risk classifications are all clinically relevant for NMIBC, but their predictive performance varies by endpoint, indicating the importance of selecting the classification according to the specific outcome of interest.”

This research has been peer-reviewed.

For more information on this research see: Comparative Analysis of Risk Stratifications for Non-muscle-invasive Bladder Cancer According To the Classifications Provided By the National Comprehensive Cancer Network, European Association of Urology, and Japanese Urological Association Guidelines. Clinical Genitourinary Cancer, 2026;24(4). Clinical Genitourinary Cancer can be contacted at: Cig Media Group, Lp, 3500 Maple Avenue, Ste 750, Dallas, TX 75219-3931, USA. (Elsevier - www.elsevier.com; Clinical Genitourinary Cancer - http://www.journals.elsevier.com/clinical-genitourinary-cancer/)

The news correspondents report that additional information may be obtained from Hiroki Ito, Yokosuka Kyosai Hospital, Dept. of Urology, Yokosuka, Japan. Additional authors for this research include Moeto Shimoda, Tetsuya Aoki, Jurii Karibe, Yosuke Shibata, Masashi Imano, Shinji Otake, Masahiro Inoue, Kazuki Kobayashi and Kazuhide Makiyama.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.clgc.2026.102560. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)